Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acadia Pharmaceutica
(NQ:
ACAD
)
14.99
+0.07 (+0.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Acadia Pharmaceutica
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
ACADIA Pharmaceuticals's Return On Capital Employed Insights
May 18, 2022
ACADIA Pharmaceuticals (NASDAQ:ACAD) brought in sales totaling $115.47 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 162.35%, resulting in a loss of $113.06...
Via
Benzinga
ACADIA Pharmaceuticals: Q1 Earnings Insights
May 04, 2022
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
May 04, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
May 03, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA Pharmaceuticals's Earnings Outlook
May 03, 2022
ACADIA Pharmaceuticals (NASDAQ:ACAD) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022
May 02, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022
April 21, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Analysts Say Acadia's Negative Pain Data Increases Focus On Pimavanserin For Alzheimer's-Related Psychosis
April 19, 2022
Via
Benzinga
Futures Flat As Yen Discombobulation Extends To Record 13th Day
April 19, 2022
After some jerky rollercoaster moves in Monday's illiquid trading session, which jerked both higher and lower before closing modestly in the green.
Via
Talk Markets
What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
April 19, 2022
ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter:
Via
Benzinga
The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu
April 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
April 19, 2022
Good morning! It's time to start off another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday!
Via
InvestorPlace
23 Stocks Moving in Tuesday's Pre-Market Session
April 19, 2022
Gainers ToughBuilt Industries, Inc. (NASDAQ: TBLT) rose 44.9% to $0.2125 in pre-market trading as the company posted a narrower FY21 loss. Sharps Technology, Inc. (NASDAQ: STSS...
Via
Benzinga
Why Acadia Pharma Shares Are Falling Today
April 19, 2022
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from a Phase 2 trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery.
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
April 18, 2022
Gainers Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million.
Via
Benzinga
Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain
April 18, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
28 Biggest Movers From Yesterday
April 12, 2022
Gainers SailPoint Technologies Holdings, Inc. (NYSE: SAIL) shares jumped 29.16% to close at $64.05 on Monday after private equity firm Thoma Bravo announced plans to acquire...
Via
Benzinga
Stocks That Hit 52-Week Highs On Thursday
April 07, 2022
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...
Via
Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
April 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...
Via
Benzinga
Acadia: Helping With Alzheimers And Parkinsons
April 03, 2022
Things always change fast in biotech, but until recently things have been moving consistently to the downside. It’s been a while, but we believe this is finally over. And we believe Acadia...
Via
Talk Markets
Stocks And Oil Drop Following The Weak Job Report
March 30, 2022
It was a strange day for the market that started with a big miss on the ADP job report.
Via
Talk Markets
9 Monster Stock Market Predictions For The Week Of March 28
March 27, 2022
It will be a critical week for stocks after weeks of gains. The S&P 500 finished Friday in an exciting spot and at more than one inflection point. It may mark the start of a bigger run higher to the...
Via
Talk Markets
Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating
March 25, 2022
Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91.
Via
Investor's Business Daily
Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)
March 22, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Wednesday Top Stock News: 8 Analyst Upgrades and Downgrades Today
March 16, 2022
We're taking a look at the top stock news for Wednesday and that includes the latest analysts upgrades and downgrades you need to know about!
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022
March 16, 2022
Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to...
Via
Benzinga
A Peek Into The Markets: US Stock Futures Gain; All Eyes On Fed Decision
March 16, 2022
Pre-open movers U.S. stock futures traded higher in early pre-market trade ahead of the interest rate decision from the Federal Reserve. Investors are awaiting earnings results...
Via
Benzinga
Expert Ratings For ACADIA Pharmaceuticals
March 03, 2022
Over the past 3 months, 18 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are typically employed by large Wall Street banks...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.